Impact of Fumonisin B1 on the Production of Inflammatory Cytokines by Gastric and Colon Cell Lines
-
Majid Mahmoodi
,
Ali Mohammad Alizadeh
,
Hamid Sohanaki
,
Nima Rezaei
,
Fatemeh Amini-Najafi
,
Ali Reza Khosravi
,
Sayed-Kazem Hosseini
,
Zahra Safari
,
Daryoush Hydarnasab
,
Vahid Khori
Abstract
Fumonisins, a family of mycotoxins, are mainly toxic and carcinogenic. The present study was carried out to evaluate fumonisin B1 (FB1) effects on the production of inflammatory cytokines by gastric and colon cell lines.
The study was performed on two cell lines under in vitro condition, including gastric epithelial cell line (AGS) and human colon adenocarcinoma cell line (SW742). Lipopolysaccharide (LPS) was used for inflammatory cytokine induction. The culture medium was supplemented with 4.5–72 mg/l of FB1 for 72 h before cell induction. The supernatants were harvested 24 h after the induction and measured for cytokines by using enzyme-linked immunosorbent assay.
FB1 induced a dose-dependent increase in the production of tumor necrosis factor-α and interleukin-1β in both AGS and SW742 cell lines. This increase was statistically significant with concentration of FB1 between 9 and 72 mg/l (P < 0.05). FB1 also induced a dose- dependent decrease in interleukin-8 production. This decrease was seen in both cell lines and showed a statistical significance with FB1 concentration (P < 0.05).
The results show that FB1 increases inflammatory cytokines production by various gastric and intestinal cells. This effect in the long run can possibly be the basis for the occurrence or development of inflammation and subsequent atrophy in the above-mentioned tissues.
1. Dutton MF. Fumonisins, mycotoxins of increasing importance: their nature and their effects. Pharmacol Ther 1996; 70(2):137–61.
2. Oswald IP, Marin DE, Bouhet S, Pinton P, Taranu I, Accensi F. Immunotoxicological risk of mycotoxin for domestic animals in Europe. Food Addit Contam 2005; 22(4):354–360.
3. Prelusky DB, Trenholm HL, Rotter BA, Miller JD, Savard ME, Yeung JM, et al. Biological fate of fumonisin B1 in food-producing animals. Adv Exp Med Biol 1996;392:265–78.
4. Merrill AH Jr, Sullards MC, Wang E, Voss KA, Riley RT. Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. Environ Health Perspect 2001; 109( Suppl 2):283–9.
5. Gelderblom WC, Snyman SD, Lebepe-Mazur S, van der Westhuizen L, Kriek NP, Marasas WF. The cancer- promoting potential of fumonisin B1 in rat liver using diethylnitrosamine as a cancer initiator. Cancer lett 1996; 109(1-2):101–8.
6. Bhandari N, Sharma RP. Fumonisin B1-induced alterations in cytokine expression and apoptosis signaling genes in mouse liver and kidney after an acute exposure. Toxicology 2002; 172(2):81–92.
7. Taranu I, Marin DE, Bouhet S, Pascale F, Bailly JD, Miller JD, et al. Mycotoxin fumonisin B1 alters the cytokine profile and decreases the vaccinal antibody titer in pigs. Toxicoll Sci 2005; 84(2):301–7.
8. Luongo D, Severino L, Bergamo P, De Luna R, Lucisano A, Rossi M. Interactive effects of fumonisin B1 and alpha-zearalenol on proliferation and cytokine expression in Jurkat T cells. Toxicol Vitro 2006;20(8):1403–10.
9. Marin DE, Gouze ME, Taranu I, Oswald IP. Fumonisin B1 alters cell cycle progression and interleukin-2 synthesis in swine peripheral blood mononuclear cells. Mol Nutr Food Res 2007; 51(11):1406–12.
10. Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007; 56(12):1696–705.
11. Takagaki K, Osawa S, Horio Y, Yamada T, Hamaya Y, Takayanagi Y, et al. Cytokine responses of intraepithelial lymphocytes are regulated by histamine H(2) receptor. J gastroenterol 2009; 44(4):285–96.
12. Szkaradkiewicz A, Marciniak R, Chudzicka-Strugała I, Wasilewska A, Drews M, Majewski P, et al. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp 2009; 57(4):291–4.
13. Dinarello CA. Proinflammatory cytokines. Chest 2000;118(2):503–8.
14. Sasaki Y, Tanaka M, Kudo H. Differentiation between ulcerative colitis and Crohn's disease by a quantitative immunohistochemical evaluation of T lymphocytes,neutrophils, histiocytes and mast cells. Pathol Int 2002; 52(4):277–85.
15. Marin DE, Taranu I, Pascale F, Lionide A, Burlacu R, Bailly JD, et al. Gender-related differences in the immune response of weaning piglets exposed to low dose of fumonisin extract. Br J Nutr 2006; 95(6):1185–92.
16. Muller G, Kielstein P, Rosner H, Berndt A, Heller M, Kohler H. Studies on the influence of combined administration of ochratoxin A, fumonisin B1, deoxynivalenol and T2 toxin on immune and defence reactions in weaner pigs. Mycoses 1999; 42(7-8):485–93.
17. Qureshi MA, Hagler WM. Effect of fumonisin-B1 exposure on chicken macrophage functions in vitro. Poultry Sci 1992; 71(1):104–12.
18. Halloy DJ, Gustin PG, Bouhet S, Oswald IP. Oral exposure to culture material extract containing fumonisins predisposes swine to the development of pneumonitis caused by Pasteurella multocida. Toxicology 2005; 213:34–44.
19. Bouhet S, Hourcade E, Loiseau N, Fikry A, Martinez S, Roselli M, et al. The mycotoxin fumonisin B1 alters the proliferation and the barrier function of porcine intestinal epithelial cells. Toxicol Sci 2004; 77:165–71.
20. Odhav B, Adam JK, Bhoola KD. Modulating effects of fumonisin B1 and Ochratoxin A on leukocytes and messenger cytokines of the human immune system. Int Immunopharmacol 2008; 8(6):799–809.
21. Riley RT, Voss KA, Norred WP, Sharma RP, Wang E, Merrill AH Jr. Fumonisins: mechanism of mycotoxicity. Rev Med Vet 1998; 149:617–26.
22. Bondy GS, Pestka JJ. Immunomodulation by fungal toxins. J Toxicol Environ Health B Crit Rev 2000; 3:109–43.
23. Qureshi MA, Garlich JD, Hagler Jr. Fusarium proliferatum culture material alters several production and immune performance parameters in White Leghorn chickens. Immunopharmacol Immunotoxicol 1995;17:791–804.
24. Chiba N, Masuda A, Yoshikai Y, Matsuguchi T.Ceramide inhibits LPS-induced production of IL-5, IL-10, and IL-13 from mast cells. J Cell Physiol 2007;213(1):126–36.
25. Bouhet S, Le Dorze E, Peres S, Fairbrother JM, Oswald IP. Mycotoxin fumonisin B1 selectively down-regulates the basal IL-8 expression in pig intestine: in vivo and in vitro studies. Food Chem Toxicol 2006; 44(10):1768–73.
26. Sharma N, He Q, Sharma RP. Amelioration of fumonisin B1 hepatotoxicity in mice by depletion of T cells with anti-Thy-1.2. Toxicology 2006; 223(3):191–201.
27. Bhandari N, Raghubir P, Sharm A. Modulation of selected cell signaling genes in mouse liver by fumonisin B1. Chem Biol Interact 2002; 139(3):317–31.
28. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 1997; 112:321–29.
29. Sansonetti PJ, Arondel J, Huerre M, Harada A, Matsushima K. Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis. Infect Immun 1999; 67(3):1471–80.
30. Zachrisson K, Neopikhanov V, Wretlind B, Uribe A.Mitogenic action of tumour necrosis factor-alpha and interleukin-8 on explants of human duodenal mucosa. Cytokine 2001; 15(3):148–55.
31. Maheshwari A, Lacson A, Lu W, Fox SE, Barleycorn AA, Christensen RD, et al. Interleukin-8/CXCL8 forms an autocrine loop in fetal intestinal mucosa. Pediatr Res 2004; 56(2):240–9.
32. Kouadio JH, Mobio TA, Baudrimont I, Moukha S, Dano SD, Creppy EE. Comparative study of cytotoxicity and oxidative stress induced by deoxynivalenol, zearalenone or fumonisin B1 in human intestinal cell line Caco-2. Toxicology 2005; 213:56–65.
33. Shephard GS, Thiel PG, Sydenham EW, Savard ME. Fate of a single dose of 14C-labelled fumonisin B1 in vervet monkeys. Nat Toxins 1995; 3:145–50.
34. Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol 2011;173(3):259–70.
35. Perri F, Terracciano F, Gentile M, Merla A, Scimeca D, Zullo A. Role of interleukin polymorphisms in gastric cancer: "Pros and cons". World J Gastrointest Oncol 2010; 2(6):265–71.
36. Chiurillo MA, Moran Y, Canas M, Valderrama E, Alvarez A, Armanie E. Combination of Helicobacter pylori-iceA2 and pro-inflammatory interleukin-1 polymorphisms is associated with the severity of histological changes in Venezuelan chronic gastritis patients. FEMS Immunol Med Microbiol 2010;59(2):170–6.
37. Yu G, Tang B, Yu PW, Peng ZH, Qian F, Sun G.Systemic and peritoneal inflammatory response after laparoscopic-assisted gastrectomy and the effect of inflammatory cytokines on adhesion of gastric cancer cells to peritoneal mesothelial cells. Surg Endosc 2010;24(11):2860–70.
38. Sugimoto M, Yamaoka Y, Furuta T. Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer. World J Gastroenterol 2010;16(10):1188–200.
39. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14(5):408–19.
40. Korstanje A, van Eeden S, Offerhaus JA, Waltman FL, Hartog G, Roelandse FW, et al. Comparison between serology and histology in the diagnosis of advanced gastric body atrophy: a study in a Dutch primary community. J clin gastroenterol 2008; 42(1):18–22.
41. Nardone G, Rocco A, Compare D, De Colibus P, Autiero G, Pica L, et al. Is Screening for and Surveillance of Atrophic Gastritis Advisable? Digest dis 2007; 25:214–7.
42. Derakhshan MH, Malekzadeh R, Watabe H, Yazdanbod A, Fyfe V, Kazemi A, et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008; 57(3):298–305.
43. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J clin invest 2007; 117(1):60–69.
44. Kato S, Kikuchi S, Nakajima S. When does gastric atrophy develop in Japanese children? Helicobacter 2008; 13(4):278–81.
45. Lee Y, Jeon YC, Koo TY, Cho HS, Byun TJ, Kim TY, et al. Histological changes of gastric atrophy and intestinal metaplasia after Helicobacter pylori eradication. Korean J Gastroenterol 2007; 50(5):299–305.
46. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J gastroenterol 2007; 17:21–7.
47. Chu FS, Li GY. Simultaneous occurrence of fumonisin B1 and other mycotoxins in moldy corn collected from the People's Republic of China in regions with high incidences of esophageal cancer. Appl Environ Microbiol 1994; 60:847–52.
48. Sydenham EW, Theil PG, Marasas WFO, Shephard GS, Van Schalkwyk DJ, Koch KR. Natural occurrence of some Fusarium mycotoxins in corn from low and high esophageal cancer prevalence areas of the Transkei, Southern Africa. J Agric Food Chem 1990; 38:1900–3.
49. Yoshizawa T, Yamashita A, Luo Y. Fumonisin occurrence in corn from high- and low risk areas forhuman esophageal cancer in China. Appl EnvironMicrobiol 1994; 60:1626–9.
50. Iijima K, Koike T, Abe Y, Inomata Y, Sekine H, Imatani A, et al. Extensive gastric atrophy: an increased risk factor for superficial oesophageal squamous cell carcinoma in japan. Am J Gastroenterol 2007;102(8):1603–9.
| Files | ||
| Issue | Vol 11, No 2 (2012) | |
| Section | Articles | |
| Keywords | ||
| Colon Fumonisin B1 Gastric IL-1β IL-8 TNF-α | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
